| Patent Number |
Title Of Patent |
Date Issued |
| RE35072 |
4-substituted pyrazolo[3,4-d]pyrimidine derivatives |
October 24, 1995 |
| 4-Substituted pyrazolo[3,4-d]pyrimidine derivatives and a method of synthesis for the derivatives are described. The 4-substituted pyrazolopyrimidine derivatives are useful as cardiotonic agents and antiarryhythmic agents. |
| RE34165 |
Potent thymopentin analogs |
January 19, 1993 |
| Immunoregulating peptides are disclosed which are more potent than thymopentin or splenin and are useful for their effects on the immune system, especially the treatment of thymic deficiencies. |
| D372867 |
Platform for a tablet dispenser package insert |
August 20, 1996 |
|
| D370414 |
Tablet dispenser insert |
June 4, 1996 |
|
| D363661 |
Tablet dispenser package |
October 31, 1995 |
|
| D298653 |
Vaginal foam applicator |
November 22, 1988 |
|
| D279504 |
Vaginal applicator |
July 2, 1985 |
|
| D263503 |
Tampon applicator |
March 23, 1982 |
|
| 6492490 |
Liquid phase peptide syntheses of KL-4 pulmonary surfactant |
December 10, 2002 |
| The invention realtes to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu.sub.4).sub.4 -Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester |
| 6491916 |
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal |
December 10, 2002 |
| The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. These "humanized" anti-CD3 monoclonal antibodies retain, in vitro, all the properties of native anti-CD3 antibodies, including T cell activation whic |
| 6437100 |
DNA encoding a human histamine receptor of the H3 subtype |
August 20, 2002 |
| DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The re |
| 6423550 |
Home oral fluid sample collection device and package for mailing of such device |
July 23, 2002 |
| This reagent strip is comprised of a testing portion which contains an absorbent cotton pad. This absorbent cotton pad may be placed in the mouth on the tongue to collect an oral fluid sample. A plastic frame surrounds the pad to help hold the fluid thereon. This testing strip contains a |
| 6413743 |
DNA encoding a human histamine receptor of the H3 subtype |
July 2, 2002 |
| DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The re |
| 6372779 |
Anti-inflammatory compounds |
April 16, 2002 |
| This invention relates to anti-inflammatory compounds, methods of making such compounds and methods of using such compounds having the following structure: ##STR1## |
| 6251956 |
Combination progestin oral contraceptive regimen |
June 26, 2001 |
| An oral contraception regimen which comprises sequentially administering two or more progestational agents exhibiting different effects on the human endometrium in combination with an estrogen. The invention is also directed to an extended use oral contraception regimen comprising the |
| 6235710 |
Spray dried erythropoietin |
May 22, 2001 |
| The present invention provides a method for preparing stable, spray dried rhEPO and the rhEPO powder produced thereby. |
| 6221608 |
Methods for identifying erythropoietin receptor binding protein |
April 24, 2001 |
| The extracellular domain of the human erythropoietin receptor (EPO binding protein, EBP) has been expressed and overproduced in E. coli. Control of oxygen levels and pH during high density fermentation allows the production of only the protein variant with the native amino terminus. |
| 6171868 |
Method of sampling bodily fluids |
January 9, 2001 |
| The invention provides for a method of making more than one punchout from a single dried blood spot. The method comprising the steps of making a first punch and sequentially making at least a second punch in the dried blood spot. The second punch comprises boundaries which are at least p |
| 6136559 |
DNA encoding as human histamine receptor of the H3 subtype |
October 24, 2000 |
| DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The re |
| 6071537 |
Anticonvulsant derivatives useful in treating obesity |
June 6, 2000 |
| A method for treating obesity comprising administering a therapeutically effective amount of a compound of the formula: ##STR1## is disclosed. |
| 6039208 |
Variable day start tablet dispenser |
March 21, 2000 |
| This invention relates to a substantially circular tablet dispenser component system which may be adapted for a variable day start of a prescribed periodic tablet regimen. Also provided are a tablet dispenser kit, a tablet package adapted for filling the tablet dispenser system, meth |
| 6028202 |
1,5-diarylpyrazoles |
February 22, 2000 |
| Compounds of Formula I ##STR1## wherein, R.sub.1 through R.sub.7 are described herein. These compounds inhibit the production of arachidonic acid products associated with 5-lipoxygenase and cyclooxygenase and are useful in the treatment of inflammatory disorders. |
| 6024938 |
Lyophilized imaging agent formulation comprising a chemotactic peptide |
February 15, 2000 |
| A lyophilized imaging agent formulation and methods for making same are disclosed, such formulations comprise a targeting molecule such as antibody or chemotactic peptide, a linker such as diethylenetriaminepentaacetic acid (DTPA) or succinimidyl 6-hydrazinium nicotinate hydrochlorid |
| 5994563 |
Arylmethylphosphonic acid derivatives useful in treating bone wasting diseases |
November 30, 1999 |
| Benzyl-phosphonate compounds represented by the formula I: ##STR1## are disclosed as useful in treating bone wasting diseases and as an immunosuppresant. |
| 5955645 |
Thrombin receptor deficient transgenic mice |
September 21, 1999 |
| A transgenic animal with alterations in an thrombin receptor gene is prepared by introduction of an altered thrombin receptor gene into a host animal. The resulting transgenic animals do not produce functional thrombin receptor molecules. |
| 5952303 |
Lyophilized pulmonary surfactant peptide compositions |
September 14, 1999 |
| An improved solid pharmaceutical composition comprising a lyophilized liposomal KL4 pulmonary surfactant composition comprising:(a) about 1 to about 10 percent weight KL4 polypeptide; and(b) 50 to about 100 weight percent phospholipid comprised of about 3 parts DPPC to about 1 part POPG.A fa |
| 5942532 |
2-substituted phenyl-benzimidazole antibacterial agents |
August 24, 1999 |
| The invention relates to benzimidazole antibacterial compounds of the Formula I: ##STR1## as described herein, pharmaceutical compositions containing the compounds, and methods for their production and use. These compounds are effective in inhibiting the action of a bacterial his |
| 5922731 |
5-[(heteroaryl)alkyl]-3-oxo-pyrido[1,2-a]benzimidazole-4-carboxamide derivatives useful in treat |
July 13, 1999 |
| A compound of the general formula 1; ##STR1## is disclosed as useful in treating disorders of the central nervous system. Pharmaceutical compositions and methods of treatment are also disclosed. |
| 5908754 |
Method for in vitro determination of in vivo erythropoeitin bioactivity |
June 1, 1999 |
| The present invention is directed to an in vitro method of determining the in vivo EPO activity of a sample containing EPO. More particularly, the present method comprises treating a sample containing EPO under conditions which remove desialylated EPO, and measuring the in vitro EPO acti |
| 5885573 |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclona |
March 23, 1999 |
| The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. This "humanized" anti-CD3 mAb (gOKT3-5) was previously shown to retain, in vitro, all the properties of native OKT3, including T cell activation whic |
| 5869674 |
Arylpyrazoles as leukotriene inhibitors |
February 9, 1999 |
| Compounds of Formula I ##STR1## useful in the treatment of inflammatory disorders. |
| 5862729 |
Mechanical punch apparatus and method of using same |
January 26, 1999 |
| A punch assembly for punching samples of dried blood spots (DBSs) from paper card samples includes: a base member, a cartridge and at least one cutting pin. The base member includes a bottom platform having an upper surface defining a track therein, an upper platform, at least one suppor |
| 5854242 |
Benzoxazine antimicrobial agents |
December 29, 1998 |
| The invention relates to benzoxazine and pyrido-oxazine antibacterial compounds of the general formula: ##STR1## wherein the moiety Q is a fused phenyl or fused pyridyl moiety as herein described, pharmaceutical compositions containing the compounds, methods for their production |
| 5843958 |
Arylpyrazoles as leukotriene inhibitors |
December 1, 1998 |
| Compounds of Formula I ##STR1## useful in the treatment of inflammatory disorders. |
| 5834521 |
Substituted dibenz (A F)azulenes and methods of preparation |
November 10, 1998 |
| Tetracyclic compounds having the following structure are described: ##STR1## wherein R.sub.1 -R.sub.10 are as defined. The tetracyclic compounds are capable of potent effects on steroid sensitive tissues and have demonstrated increased uterine weight, antiovulatory effects and potent |
| 5833072 |
Dosage regimen container |
November 10, 1998 |
| Generally, this invention relates to dosage containers. More specifically this invention relates to dosage containers which help identify a daily regimen of dosages, or a particular time period of dosages in a day. Most specifically, this invention relates to a dosage container which pro |
| 5827866 |
Peptidyl heterocycles useful in the treatment of thrombin related disorders |
October 27, 1998 |
| Compounds of the Formula I: ##STR1## useful in the treatment of thrombin and trypsin related disorders. |
| 5827860 |
Peptidyl heterocycles useful in the treatment of thrombin related disorders |
October 27, 1998 |
| Compounds of the Formula I: ##STR1## useful in the treatment of thrombin and trypsin related disorders. |
| 5817668 |
S-heteroatom containing alkyl substituted-3-oxo-pyrido[1,2-A]benzimidozole-4-carboxamide derivat |
October 6, 1998 |
| A compound of the general formula 1; ##STR1## is disclosed as useful in treating disorders of the central nervous system. Pharmaceutical compositions and methods of treatment are also disclosed. |
| 5799821 |
Variable day start tablet dispenser |
September 1, 1998 |
| This invention relates to a substantially circular tablet dispenser component system which may be adapted for a variable day start of a prescribed periodic tablet regimen. Also provided are a tablet dispenser kit, a tablet packge adapted for filling the tablet dispenser system, metho |
| 5792444 |
Labeled chemotactic peptides to image focal sites of infection or inflammation |
August 11, 1998 |
| The invention relates to a method of detecting a site of infection or inflammation, and a method for treating such infection or inflammation, in an individual by administering to the individual a diagnostically or therapeutically effective amount of detectably labeled, therapeutic, or |
| 5783597 |
2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) |
July 21, 1998 |
| 2,5-Disubstituted thiophene derivatives, and more particularly, to 2-aryloxy-5-alkansulfonamido-thiophenes of the general formula: ##STR1## Wherein, R.sub.2 is CF.sub.3, C.sub.1 -C.sub.10 alkyl, or phenyl;X is O, S, or CH.sub.2 ; andR is aryl, C.sub.1 -C.sub.10 alkyl, or C.sub.3 -C.sub.8 |
| 5773469 |
Diaryl antimicrobial agents |
June 30, 1998 |
| The invention relates to diaryl antimicrobial compounds of the general formula: ##STR1## where G, E L, J, q, m, X, Ar, W, p, n and A are as described herein, pharmaceutical compositions containing the compounds, methods for their production and their use in treating bacterial inf |
| 5770575 |
Nipecotic acid derivatives as antithrombotic compounds |
June 23, 1998 |
| Nipecotic acid-derived compounds of formula (I): ##STR1## are disclosed as useful in treating platelet-mediated thrombotic disorders. |
| 5760007 |
Anticonvulsant derivatives useful in treating neuropathic pain |
June 2, 1998 |
| Anticonvulsant derivatives useful in treating neuropathic pain are disclosed. |
| 5760006 |
Anticonvulsant derivatives useful in treating psoriasis |
June 2, 1998 |
| The use of compounds of the following formula I: ##STR1## for treating psoriasis is disclosed. |
| 5753715 |
2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents |
May 19, 1998 |
| The invention relates to cyclohexenyl antibacterial compounds of the formula I: ##STR1## and pharmaceutical compositions containing the compounds, methods for their production and use. |
| 5753694 |
Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
May 19, 1998 |
| Disclosed herein is a method of treating amyotrophic lateral sclerosis with topiramate and related compounds. |
| 5753693 |
Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
May 19, 1998 |
| This application relates to the use of topiramate and related sulfonamides for the treatment of manic-depressive bipolar disorder. |
| 5753655 |
1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of prepara |
May 19, 1998 |
| 1-Arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and processes for making said derivatives are described. The novel derivatives are non-steroidal heterocyclic compounds which act as selective progestins and/or antiprogestins having a high in-vitro affinity fo |
